Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
On Tuesday, Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release ...
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...
Hosted on MSN21d
Silexion reports breakthrough in KRAS cancer therapySilexion Therapeutics, known for its pioneering work in RNAi therapies, has previously achieved promising results in a Phase 2 trial with its first-generation product, LODER™, for non-resectable ...
What is the current share price of Silexion Therapeutics Corp (SLXN)? Silexion Therapeutics Corp's (SLXN) current share price is $1.08. This constitutes a price movement of 14.29% when compared to the ...
Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results